2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) All Versions of this Article: ASN.2007010125v1 18/5/1374    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rossetti, S. Articles by Harris, P. C. Search for Related Content PubMed PubMed Citation Articles by Rossetti, S. Articles by Harris, P. C.

Genotype–Phenotype Correlations in Autosomal Dominant and Autosomal Recessive Polycystic Kidney Disease

Division of Nephrology and Hypertension, Mayo Clinic College of Medicine, Rochester, Minnesota

Address correspondence to: Dr. Peter C. Harris, Division of Nephrology, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905. Phone: 507-266-20541; Fax: 507-2266-29315; E-mail: harris.peter{at}mayo.edu

The phenotypes that are associated with the common forms of polycystic kidney disease (PKD)—autosomal dominant (ADPKD) and autosomal recessive (ARPKD)—are highly variable in penetrance. This is in terms of severity of renal disease, which can range from neonatal death to adequate function into old age, characteristics of the liver disease, and other extrarenal manifestations in ADPKD. Influences of the germline mutation are at the genic and allelic levels, but intrafamilial variability indicates that genetic background and environmental factors are also key. In ADPKD, the gene involved, PKD1 or PKD2, is a major factor, with ESRD occurring 20 yr later in PKD2. Mutation position may also be significant, especially in terms of the likelihood of vascular events, with 5' mutations most detrimental. Variance component analysis in ADPKD populations indicates that genetic modifiers are important, but few such factors (beyond co-inheritance of a TSC2 mutation) have been identified. Hormonal influences, especially associated with more severe liver disease in female individuals, indicate a role for nongenetic factors. In ARPKD, the combination of mutations is critical to the phenotypic outcome. Patients with two truncating mutations have a lethal phenotype, whereas the presence of at least one missense change can be compatible with life, indicating that many missense changes are hypomorphic alleles that generate partially functional protein. Clues from animal models and other forms of PKD highlight potential modifiers. The information that is now available on both genes is of considerable prognostic value with the prospects from the ongoing genetic revolution that additional risk factors will be revealed.

This article has been cited by other articles:

				O. Symmons, A. Varadi, and T. Aranyi How Segmental Duplications Shape Our Genome: Recent Evolution of ABCC6 and PKD1 Mendelian Disease Genes Mol. Biol. Evol., December 1, 2008; 25(12): 2601 - 2613. [Abstract] [Full Text] [PDF]

				C. Bergmann, N. O. Bruchle, V. Frank, H. Rehder, and K. Zerres Perinatal Deaths in a Family with Autosomal Dominant Polycystic Kidney Disease and a PKD2 Mutation N. Engl. J. Med., July 17, 2008; 359(3): 318 - 319. [Full Text] [PDF]

				K Nozu, T Inagaki, X J Fu, Y Nozu, H Kaito, K Kanda, T Sekine, T Igarashi, K Nakanishi, N Yoshikawa, et al. Molecular analysis of digenic inheritance in Bartter syndrome with sensorineural deafness J. Med. Genet., March 1, 2008; 45(3): 182 - 186. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673